Idebenone (RAXONE) Cardiac Function Study in DMD
TerminatedPhase 3Other Therapeutic Approaches
Study Overview
- Age
- 10–18 years
- Phase
- Phase 3
- Sponsor
- Santhera Pharmaceuticals
- Therapeutic Approach
- Other Therapeutic Approaches
- Variant Requirement
- Any confirmed DMD diagnosis
- Eligible Sex
- Male
- Ambulation
- Ambulatory and Non-Ambulatory
- Countries
- United StatesGermanyFranceUnited KingdomItalySpain
Study Requirements and Criteria
Steroid Use
No steroid requirement; background use documented
Inclusion Criteria
Male aged 10–18 with confirmed DMD. Evidence of cardiac involvement. Willing to undergo cardiac MRI.
Exclusion Criteria
Severe cardiac failure requiring hospitalization. Contraindication to MRI. Prior idebenone use within 4 weeks.
Clinical Trial Registry
NCT ID
NCT02814019This information is provided for educational purposes only. Always consult the study investigators before making medical decisions.